Compugen Ltd.
https://www.cgen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Compugen Ltd.
Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio
The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.
Finance Watch: Biotech Stocks Down, But Holding Up Better Than Broader Indices
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.
Israel Looks To Nurture New Leaders For Burgeoning Biotech Sector
While Israel has not wanted for early-stage scientific excellence, leading lights in the country's biotech space are working to create an ecosystem where clinical, regulatory and managerial expertise can develop.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Large Molecule
- Other Names / Subsidiaries
-
- Evogene, Compugen USA, Inc, Neviah Genomics Ltd